Cargando…

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment

Endocrine therapy is an effective treatment for low-grade serous ovarian cancer. However, the role of estrogen and progesterone receptors as biomarkers for high-grade serous ovarian cancer (HGSOC) is yet to be elucidated because not all estrogen and progesterone receptor-positive tumors benefit from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vetter, Marcus, Stadlmann, Sylvia, Bischof, Evelyne, Georgescu Margarint, Elena Laura, Schötzau, Andreas, Singer, Gad, Heinzelmann-Schwarz, Viola, Montavon, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692716/ https://www.ncbi.nlm.nih.gov/pubmed/36430718 http://dx.doi.org/10.3390/ijms232214242

Ejemplares similares

Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience
por: Bischof, Evelyne, et al.
Publicado: (2021)

L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy
por: Zeiter, Deborah, et al.
Publicado: (2021)

Outcome in serous ovarian cancer is not associated with LATS expression
por: Montavon, Céline, et al.
Publicado: (2019)

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer
por: Saner, Flurina AM, et al.
Publicado: (2019)

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers
por: Sartorius, Céline Montavon, et al.
Publicado: (2018)

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
por: Baettig, Florence, et al.
Publicado: (2019)

Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience
por: Biskup, Ewelina, et al.
Publicado: (2023)

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
por: Jacob, Francis, et al.
Publicado: (2020)

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers
por: Montavon, Celine, et al.
Publicado: (2018)

Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial
por: Amstad, Gabriela, et al.
Publicado: (2022)

An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting
por: Vigo, Francesco, et al.
Publicado: (2021)

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer
por: Montavon Sartorius, Céline, et al.
Publicado: (2018)

Viropathic multinuclear syncytial giant cells in bronchial fluid from a patient with COVID-19
por: Stadlmann, Sylvia, et al.
Publicado: (2020)

Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study
por: Zwimpfer, Tibor A., et al.
Publicado: (2021)

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients
por: Pochechueva, Tatiana, et al.
Publicado: (2017)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
por: Iyengar, Mangala, et al.
Publicado: (2018)

The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells
por: Ford, Caroline E., et al.
Publicado: (2013)

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
por: Bischof, Katharina, et al.
Publicado: (2019)

The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy
por: Singer, Gad, et al.
Publicado: (2022)

Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
por: McLaughlin, Pamela M. J., et al.
Publicado: (2022)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma
por: Anugraham, Merrina, et al.
Publicado: (2017)

Bilateral Breast Masses with a Rare Etiology
por: Thieringer, Friederike, et al.
Publicado: (2013)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
por: Feng, Zheng, et al.
Publicado: (2017)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

High-throughput approaches for precision medicine in high-grade serous ovarian cancer
por: Govindarajan, Meinusha, et al.
Publicado: (2020)

A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
por: Feng, Zheng, et al.
Publicado: (2016)

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)
por: Feng, Zheng, et al.
Publicado: (2017)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy
por: Walther, Fabio, et al.
Publicado: (2022)

CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
por: Kleinmanns, Katrin, et al.
Publicado: (2020)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ilsfbobfgaags4vq5m8tr6ef3k